Introduction
The discovery that umbilical cord blood (UCB) hematopoietic stem cells (HSC) could be used as an alternative source to rescue myeloablated pediatric patients broadened the bone marrow (BM) transplantation treatment modality. However, reconstitution of hemopoiesis after intensive chemotherapy and grafting of UCB cells in children and even more in adults is slower compared to the use of BM or mobilized peripheral blood grafts. 1 This prolonged period of aplasia results in increased risk for infections and bleeding in patients. The limited potential for rapid hematological recovery after transplantation of UCB cells is probably due to a limited number of nucleated cells and HSC transplanted per kg BW, and may therefore be abrogated by ex vivo generation of the required numbers of stem and progenitor cells. Expansion studies might also increase our current knowledge on the regulation of hem-opoiesis, contribute to new treatment strategies of hematological diseases and aid in manipulating stem cells as vehicles for gene therapy.
Although ample studies on the culture of CD34 + UCB cells have been published over the last years, and expansion of committed progenitors has been reported, the ability to expand more primitive HSC has met with little success. 2 The most promising results have been obtained after the introduction of FL, the ligand of the class III tyrosine kinase receptor FLT3, and TPO, the ligand of the c-mpl receptor, both receptors are expressed on early and committed hematopoietic progenitors. Analysis of the effect of 16 cytokines on stroma-free cultures of CD34 +
CD38
− bone marrow cells indicated that FL, SCF and IL3 gave the highest (30-fold) expansion of the input long-term culture-initiating cells (LTC-IC). 3 In another study addition of FL maintained the ability of human CD34
+ cells to sustain long-term hematopoiesis. 4 TPO has also been reported to increase the multilineage growth of CD34 + CD38 − bone marrow cells under stroma-free conditions when added to the cytokine combination FL and SCF. 5 The presence of additional cytokines, eg IL3, IL6 and EPO did not significantly enhance the colony formation above that observed with FL, TPO and SCF. Others demonstrated that maximal expansion of progenitors by FL + IL11 required a longer incubation than with SCF + IL11 indicating involvement of different kinetics in enhanced production of progenitors. 6 A major step toward extensive ex vivo amplification of early human progenitors has been reported by Piacibello et al. These authors demonstrated that IL3 induced production of committed progenitors and was unable to sustain maintenance of hematopoietic stem cells. Among the various early acting cytokine combinations tested for their ability to sustain long-term hematopoiesis in stroma-free cultures using CD34 + UCB cells, FL and TPO were found to be necessary and sufficient to maintain early progenitors for several months. [7] [8] [9] Until recently, investigators have included CD34
+ cells, or subsets, and LTC-IC or cobblestone area forming cell (CAFC) in vitro assays to measure the HSC activity after expansion studies, but few have evaluated the genetically immunodeficient mice repopulating ability of these expanded HSC. [10] [11] [12] In HSC expansion studies, investigators also emphasized the role played by microenvironment, with stromal cells as essential components. Multiple mechanisms have been proposed to explain the regulatory effect of stromal cells on HSC functions such as survival of quiescent cells, increased proliferation and differentiation, or decreased cell proliferation mediated by contact with stromal elements. 2, 13, 14 However, there is incomplete evidence as to whether expansion of NOD/SCID repopulating cells (SRC) is increased in the presence of a BM-derived stromal layer. In the present study we examined if HSC expansion in the presence of BM-derived stromal cells, in synergy with potent cytokines over 2 weeks, will alter the in vivo long-term engraftment potential of CD34 + UCB cells and which cytokines are required in the presence or absence of stroma. Both in vitro (CAFC) and in vivo (SRC) HSC assays that have been reported to correlate with (multilineage) engraftment potential have been used simultaneously in each experiment, to evaluate the changes of cultured cells from different perspectives. We demonstrate that stroma is not required for NOD/SCID repopulating ability in 2-week cultures by a combination of cytokines when FL and TPO are included.
Materials and methods

Human umbilical cord blood cells
Human UCB samples were collected from umbilical cord vein after full-term delivery by the nursing staff of the Department of Obstetrics and Gynecology at the Sint Franciscus Gasthuis (Rotterdam, The Netherlands). Informed consent for taking samples for clinical study was obtained. UCB was collected in sterile flasks containing 10 ml citrate-glucose as anticoagulant, stored at room temperature and processed within 24 h of collection.
Isolation of CD34
+ cells
Low-density cells were isolated using Ficoll-Hypaque density centrifugation (1.077 g/cm 2 ), Lymphoprep; Nycomed Pharma, Oslo, Norway). After centrifugation at 600 g for 15 min, the mononuclear cell (MNC) band at the interface was removed, washed twice with Hank's balanced salt solution (HBSS; Gibco, Breda, The Netherlands) and resuspended in Iscove's modified Dulbecco's medium (IMDM; Gibco). The MNCs were stored in liquid nitrogen until use. After thawing and before the CD34 + hematopoietic progenitor cells were isolated we pooled five to 20 different UCB samples. The CD34 + cells were harvested from the mononuclear cells using Variomacs Immunomagnetic Separation System (Miltenyi Biotec, Bergisch Gladbach, Germany). The CD34 + cells were labeled indirectly using a hapten-conjugated primary monoconal antibody and an anti-hapten antibody coupled to MACS microbeads. The magnetically labelled cells were enriched by passing them twice through a Variomacs positive selection column to reach a final purity of Ͼ90% CD34 + cells. A nuclear cell count was performed and the progenitor and stem cell numbers in the CD34 + -selected UCB cells were assayed by CFC, CAFC and NOD/SCID repopulating cell assays. In addition, the immunophenotypic characteristics of the cells were assessed and part of the CD34 + cells were cultured for 2 weeks.
Hematopoietic growth factors
The following cytokines were used: recombinant human stem cell factor (SCF) and FLT3-ligand (FL), both gifts from Amgen (Thousand Oaks, CA, USA); recombinant human interleukin 6 (IL6), recombinant human granulocyte-macrophage colonystimulating factor (G-CSF), recombinant human granulocyte colony-stimulating factor (G-CSF), murine stem cell factor (SCF), all gifts from Genetics Institute (Cambridge, MA, USA); recombinant human thrombopoietin (TPO, a gift from Genentech, South San Francisco, CA, USA), recombinant human erythropoietin (EPO, Boehringer, Mannheim, Germany) and IL3 (Gist Brocades, Delft, The Netherlands).
Leukemia
Ex vivo expansion cultures
Various culture conditions were used in 10 consecutive experiments. In the first two experiments 50 000 CD34 + UCB cells were cultured in tissue culture six-well plates (Costar, Badhoevedorp, The Netherlands) in a 1 ml IMDM-cocktail containing 10% fetal calf serum (FCS; Summit, Fort Collins, CO, USA), 1% bovine serum albumin (BSA; Sigma, Zwijndrecht, The Netherlands) supplemented with penicillin (100 U/ml, Gibco), streptomycin (0.1 mg/ml, Gibco), ␤-mercapto-ethanol (10 −4 m, Merck, Darmstadt, Germany), bovine insulin (4 mg/ml, Gibco), cholesterol (15 m, Sigma), linolic acid (15 m, Merck) iron-saturated human transferrin (0.62 g/l, Intergen, Uithoorn, The Netherlands), cytidine (10 −3 g/ml, Sigma), adenosine (10 −3 g/ml, Sigma), uridine (10 −3 g/ml, Sigma), guanosine (10 −3 g/ml, Sigma), 2Ј-deoxycytidine (10 −3 g/ml, Sigma), 2Ј-deoxyadenosine (10 −3 g/ml, Sigma), thymidine (10 −3 g/ml, Sigma), 2Ј-deoxyguanosine (10 −3 g/ml, Sigma) and the cytokines FL (50 ng/ml), TPO (10 ng/ml), SCF (100 ng/ml), IL6 (100 ng/ml). The cells were cultured with the following combination of cytokines: FL + TPO, FL + TPO + SCF, FL + TPO + IL6, FL + TPO + SCF + IL6 or SCF + IL6. Cultures were set up using six to eight replicates of each cytokine combination. Additionally, 50 000 CD34 + cells were deposited in tissue culture 25T-flasks in 4 ml IMDM-cocktail containing 20% FCS with these same cytokine combinations. Cells were also cultured in the absence of cytokines. In the following part of the study, 645 000 or 700 000 CD34 + cells were cultured in tissue culture 175T-flasks (Falcon, Etten-Leur, The Netherlands) with the cytokine combination FL + TPO + IL6 in 10 ml IMDM-cocktail without BSA containing 5, 10 or 20% FCS. Finally, 35 000 or 40 000 CD34 + cells were deposited in tissue culture 25T-flasks in 4 ml IMDM-cocktail without BSA containing 20% FCS supplemented with the following cytokines: FL + TPO, FL + TPO + SCF, FL + TPO + SCF, FL + TPO + SCF + IL6. The effect of the murine FBMD-1 stromal layer on the in vitro and in vivo repopulating ability was assessed for the cytokines FL + TPO, FL + TPO + IL6, FL + TPO + SCF + IL6, and SCF + IL6. Insulin was not added in the stromal groups because it potently stimulated adipogenesis in FBMD-1 cells.
In the second part of the study, 350 000 and 775 000 CD34 + UCB cells were cultured in tissue culture 175T-flasks using 10 or 18 ml Cellgro stem cell growth medium (SCGM; Boehringer Ingelheim, Heidelberg, Germany) with or without 10% FCS supplemented with the cytokine combinations FL + TPO, FL + TPO + SCF + IL6, FL + TPO + IL6 or SCF + IL6. In the last set of experiments, 40 000 CD34 + cells were deposited in tissue culture 25T-flasks in 4 ml SCGM containing 20% FCS supplemented with the following cytokines: FL + TPO, FL + TPO + SCF, FL + TPO + IL6 or FL + TPO + SCF + IL6. The effect of the murine FBMD-1 stromal layer on the in vitro and in vivo repopulating ability was assessed for the cytokines FL + TPO, FL + TPO + IL6, FL + TPO + SCF + IL6 and SCF + IL6. Cells were also deposited on a stromal layer without any cytokine supplements. SCGM without insulin was used in stromal groups to prevent adipocyte formation. In all experimental sets FL and TPO were added twice a week to the expansion cultures.
The cultures were maintained at 37°C and 10% CO 2 in a humidified atmosphere and terminated at week 2 by collecting the supernate after scraping each well or flask with a cell scraper to include all the adherent cells. The stromal groups were first trypsinized with trypsin-EDTA (Life Technologies, Breda, The Netherlands). The content of the various dishes or flasks belonging to a single group were pooled, centrifugated at 250 g for 10 min and resuspended in IMDM. Suitable aliquots of the output suspensions were assayed in CFC, CAFC and SRC assays for determination of progenitor and stem cell numbers. In addition, the immunophenotypic characteristics of the cultured cells were analyzed.
Clonogenic assay
Granulocyte-macrophage colony-forming unit (CFU-GM) and burst forming unit-erythroid (BFU-E) progenitor cells were assayed using a semisolid culture medium (1.2% methylcellulose), containing IMDM supplemented with 10% FCS, ␤-mercapto-ethanol (5 × 10 −5 m), penicillin (100 U/ml), streptomycin (0.1 mg/ml), hu-EPO (1 U/ml), hu-IL3 (20 ng/ml), hu-GM-CSF (5 ng/ml), hu-G-CSF (50 ng/ml) and mu-SCF (100 ng/ml). Duplicate cultures were plated in 35-mm tissue culture dishes (Falcon) and incubated at 37°C and 10% CO 2 in a humidified atmosphere for 14 days. Colonies containing 50 cells or more were scored at day 14 using an inverted light microscope.
Cobblestone area forming cell assay
Confluent stromal layers of FBMD-1 cells in flat-bottom 96-well plates (Falcon) were overlaid with UCB cells in a limiting dilution set up as described. 15 Briefly, 12 successive two-fold dilutions were used for each sample with 15 wells per dilution. The percentage of wells with at least one phase-dark hematopoietic clone (cobblestone area) of at least five cells beneath the stromal layer was determined at week 2, 4 and 6. At initiation of the cultures 250 CD34
+ UCB cells per well were plated in the first dilution, while after 2 weeks of cultures 200-1000 CD34
+ input equivalent cells per well were used in the first dilution. The CAFC frequencies were calculated using Poisson statistics.
Immunophenotypic analysis
At least 50 000 fresh or cultured CD34
+ cells or femoral bone marrow cells of the NOD/SCID mice were stained with antihuman CD45/CD33, CD34/CD38, CD34/CD19 (fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated) labeled monoclonal antibodies (Immunotech, Mijdrecht, The Netherlands). To analyze the lineage commitment the femoral bone marrow cells were also stained with anti-human CD15/CD33, CD41/CD33, glycophorin A (GlyA), CD20/CD19, CD3/CD4 and CD3/CD8. After incubation of the cells in phosphate-buffered saline (PBS, Life Technologies) containing 0.5% BSA and 2% normal human serum for 30 min on ice, the cells were washed in PBS with 0.5% BSA and resuspended in 0.35 ml PBS. Just before the acquisition, 7-aminoactinomycin (7-AAD; Molecular Probes, Leiden, The Netherlands) was added to each sample to determine the viability of the cells. FITC and PE-conjugated mouse isotype antibodies were used as control for each group. At least 10 000 events were acquired using fluorescence-activated cell sorting (FACS) analysis (Becton Dickinson).
NOD/SCID repopulating cell (SRC) assay
Specific pathogen free (SPF) NOD/LtSz-SCID/SCID (NOD/SCID) mice, 6 to 15 weeks of age, were used as recipients of human cell grafts. The NOD/SCID mice were bred, maintained and used under SPF conditions in a laminar airflow unit, supplied with sterile food and acidified drinking water containing 100 mg/ml ciprofloxacine. All mice were sublethally irradiated with 3.5 Gy from a 137 Cs source (Gammacell; Atomic Energy of Canada, Ottawa, Canada) 1 to 4 h prior to intravenous transplantation. At day 0 of the experiments, 50 000 or 100 000 CD34 + cells and on week 2 of the cultures 5000 and 50 000 input equivalent cells were transplanted. The number of mice used for each group varied from three to four. Six weeks after transplantation mice were killed by CO 2 inhalation and bone marrow cells were harvested by flushing all cells from two isolated femurs per animal. After counting, the cells were analyzed by FACS to determine the human cell engraftment in each mouse. Between 10 000 and 100 000 events were acquired for analysis. If the percentage of CD45
+ cells was Ͼ0.1% the mice were considered positive, while all mice with a percentage Ͼ1.5% were analyzed for expression of lineage-specific markers.
Statistical analysis
The values are reported as mean ± s.d. The significance levels were determined by two-tailed Mann-Whitney test analysis.
Results
Characteristics of uncultured CD34
Highly purified CD34 + UCB cells were cultured in an attempt to expand the graft content of primitive stem cells using serum-containing and serum-free conditions supplemented with two or more cytokines and in the presence or absence of a murine FBMD-1 stromal layer. After isolation of the MNC by low-density gradient from a pool of five to 20 UCB samples, immunomagnetic selection according to the CD34 antigen expression was performed. The purity of the selected cells, determined by FACS after staining with CD34-FITC conjugated monoclonal antibody, varied between 88% and 97%. + UCB cells was also obtained (Table 1 ). The maximum recovery of CFU-GM in stroma-free cultures was 42 ± 40-fold the input (Figure 2 ), while the BFU-E were lost in all cytokine groups. In general, there was a higher fold increase of CD34 +
CD38
− cells than of CD34 + cells. If this phenotype CD34 + CD38 − truly predicts the expansion of long-term repopulating cells, then it would be likely to find similar dramatic expansion of the absolute number of CAFC subsets and SRC as well. However, the CAFC week 2 and 6 were maximally four-and 11-fold expanded, respectively, while in some cytokine combinations (i.e. FL + TPO and SCF + IL6) even less CAFC week 2 and 6 than input were recovered (Figure 2 ). The addition of SCF ± IL6 to the cytokine combination FL + TPO promoted the early and late progenitor amplification in terms of CFU-GM and CAFC subsets, indicating a synergistic effect of these cytokines in combination with FL + TPO. As can be seen from Figure 2 , the optimal cytokine combination for expansion of hematopoietic progenitors (CFU-GM, CAFC) under stromafree conditions was FL + TPO + SCF + IL6.
Following 2 weeks of culture, a considerable expansion of the potential of CD34
+ UCB cells to engraft the BM of sublethally irradiated NOD/SCID mice was also observed. The maximum levels of BM engraftment obtained for each group of mice infused with cultured cells is shown in Figure 3 . When cells had been cultured in the presence of FL + TPO + SCF, up to 90% of the BM cells were of human origin, while culture with SCF + IL6 alone led to human chimerism levels below that of uncultured CD34 + UCB cells. In all other cytokine combination groups, higher levels of human chimerism were detected in mice injected with cultured cells than in mice infused with uncultured CD34 + UCB cells (Figure 4) . Addition of SCF ± IL6 to the cytokine combination FL + TPO elicited no significant effect on the estimated expansion of the SRA. The cultured cells also showed an increased ability to repopulate the mice with CD34 + and CD34 − (1.4% of all bone marrow cells) was found in mice infused with cells cultured in the presence of FL + TPO + IL6 and FL + TPO, respectively. Figure 5 shows the level of human engraftment at 6 weeks after transplantation of the NOD/SCID mice with 5000 rather than 50 000 input equivalent cells. Even these limited cell numbers were similarly able to engraft 100% of the mice. The percentage of human engraftment ranged between 0.1% and 47%, with the highest value was observed for the cytokine combination FL + TPO + IL6. Although the engraftment capacity of the cells cultured with either FL + TPO or SCF + IL6 was lower as compared to other cytokine combinations, these 5000 input equivalent cells gave the same (using FL + TPO and FL + TPO + SCF ± IL6 under stroma-free and stromasupported conditions, respectively) or an even higher (using FL + TPO + IL6) human engraftment than did 100 000 CD34 + uncultured cells. This strongly substantiates our contention that the ability of the cells to give engraftment in the bone marrow of NOD/SCID mice can be expanded in a 2-week culture system. Assuming a linear relation between the number of input equivalent cells transplanted and the level of chimerism found in the BM of NOD/SCID mice we have estimated the expansion of in vivo engraftment ability of cultured 2.9 ± 2.7 4.1 ± 4.5 3237 ± 4997 FL + TPO + SCF + IL-6; n = 2 3.0 ± 1.2 2.9 ± 0.1 631 ± 146 SCF + IL-6; n = 2 0.7 ± 0.8
The data represent the mean fold-increase ±s.d. of two to seven experiments performed, in which CD34 + UCB cells were cultured for 2 weeks under stroma-free and stroma-supported conditions with or without cytokines. ND, not determined; n, no. of experiments.
CD34
+ UCB cells, as we realized that the expansion in mice with high chimerism percentages could be underestimated. As shown in Table 3 , all cytokine combinations except for SCF + IL6 led to a more than an average of 10-fold SRA expansion.
In order to evaluate whether the expanded cells maintained their ability for multilineage engraftment in the NOD/SCID mice we studied the expression of lineage markers on the human cells present in the femoral marrow of the mice at 6 weeks post-transplant. We did not observe a significant difference between the ability of the cultured and uncultured cells to produce various progenitors (CD34 
Stroma-supported cultures:
To investigate whether stromal support would improve the maintenance and/or expansion of primitive stem cells, we inoculated the CD34 + UCB cells on a murine stromal layer using the same liquid culture set-up as used for stroma-free cultures except for insulin. Cultures were either supplemented with FL + TPO, SCF + IL6 or FL + TPO ± SCF ± IL6. Stroma-supported cultures without additional cytokines were included as a control. From Figures 1 and 2 it is clear that stroma support without additional cytokines did not lead to an expansion of CFU-GM, CAFC subsets and CD34 + cells, however, it gave a 20 ± 17-fold increase of the CD34 + CD38 − subset. In the presence of FL + TPO, stromal support synergized to give a significantly higher expansion of all parameters studied, except of CD34 + cells as compared to stroma-free culture (P Ͻ 0.05). Stromal support could be fully replaced by complementation of the FL + TPO stimulated cultures with SCF + IL6. In the presence of FBMD-1 stromal cells, the total fold-expansion could not be significantly improved by other cytokine combinations. Also in the presence of FL + TPO + SCF, or FL + TPO + IL6, stroma-support stimulated the average expansion of nc, CD34
+ , CD34 + , CD38 − cells, although not always significantly. In the presence of stroma, SCF + IL6 stimulated remarkably few total nc, CD34
+ cells and CFU-GM, and did not prevent loss of CAFC week 2 and 6, while it also did not give an improved maintenance of all parameters as compared to non-stroma-supported cultures. Stromal support alone was not sufficient to maintain the SRA of CD34 + , UCB cells in 2-week cultures. FL + TPO were required and sufficient to give a comparable high SRA expansion under stroma-supported cultures as compared to stromafree cultures. Stromal support, or complementation of the medium with SCF + IL6, did not significantly improve the NOD/SCID BM engraftment potential (Figures 4 and 5 ).
Discussion
Our data show a more than 10-fold expansion of CAFC week 6 and of the potential of CD34 + UCB cells to multilineage engraft the BM of sublethally irradiated NOD/SCID mice after 2 weeks of both stroma-free and stroma-supported culture in the presence of at least FL + TPO. Among the cytokine combinations tested, stroma significantly improved the maintenance of CAFC week 6 with the cytokine combination FL + TPO. This stromal support could be replaced by adding additional SCF + IL6 to the FL + TPO stimulated cultures. However, neither stromal support nor complementation of the medium with SCF + IL6 improved the in vivo engraftment potential of 2-week cultured CD34
+ UCB cells. The four cytokines used in the present study were chosen due to their key involvement in previous expansion studies, as well as being early acting cytokines. For example, while TPO induces apoptosis with down-regulation of CD44 in CD34 + UCB cells, FL does not. 16 In contrast, the continuous presence of TPO in stromal cultures resulted in generation of both short-and long-term in vivo repopulating HSC. 17 In the
Figure 2
Fold-expansion of absolute number of colony forming unit granulocyte-macrophage (CFU-GM) and cobble stone area forming cell (CAFC) subsets following 2 weeks of culture of CD34 + UCB cells under stroma-free and stroma-supported conditions with or without cytokines. Data represent the mean (s.d.) of 2-11 experiments performed. Mann-Whitney test: *denotes significant difference (P Ͻ 0.05) between stroma-supported cultures with cytokines and stromasupported culture without cytokines; # denotes significant difference (P Ͻ 0.05) between stroma-supported cultures and FT stroma-free culture. FT, FL + TPO; FTS, FL + TPO + SCF; FT6, FL + TPO + IL6, FTS6, FL + TPO + SCF + IL6; S6, SCF + IL6.**, All cells died. present study, the results following 2-week cultures have shown FL + TPO + SCF + IL6 under stroma-free conditions to represent an optimum cytokine combination for expansion of early and late progenitors. The addition of SCF ± IL6 to the combination FL + TPO enhanced progenitor cell expansion in terms of CFU-GM and CAFC subsets. These data indicate a synergistic effect of SCF ± IL6 with FL and TPO in our 2-week stroma-free culture system, which is in contrast with previous data published by Piacibello et al indicating no difference in the extent of early progenitors to substantial addition of SCF ± IL6. This may reflect differences in the sources of cytokines, the purification procedures of cell populations or the presence of uncharacterized factors in the sera.
One of the essential issues remaining to be clarified was the assessment of in vivo repopulating ability of expanded cells. In our 2-week culture system we obtained a considerable expansion of cells capable of multilineage outgrowth in the Leukemia BM of NOD/SCID mice. Luens et al 18 reported that human CD34 + CD38 − bone marrow cells after 6 days stroma-free culture sustained, but not expanded, their in vivo repopulating ability in the qualitative SCID/hu bone assay. A modest increase of competitive repopulating units was observed after 5-8 days stroma-free culture of CD34 + CD38 − UCB cells in the presence of cytokines FL, SCF, IL3, IL6 and G-CSF. 19 Similarly, Bhatia et al 10 reported that under serum-free conditions a two-to four-fold increase of SRC could be obtained after 4 days culture of CD34 + CD38 − UCB cells, while after 9 days of culture all SRC were lost. All these data support the contention that in contrast to CFU-GM, SRC are difficult to expand, while they are rapidly lost in culture. In the present study, the expansion of the ability of CD34
+ UCB cells to multilineage engraft the BM of sublethally irradiated NOD/SCID mice following 2-week stroma-free cultures was observed in the presence of various cytokine permutations including FL + TPO and SCF + IL6. Remarkably, addition of SCF ± IL6 to the cytokine combination FL + TPO showed no significant effect on the estimated expansion of the engraftment ability. While preparing this manuscript Piacibello et al 11 showed that more than 70-fold SRC increase could be obtained after 9 to 10 weeks culture of CD34 + UCB cells under stroma-free conditions in the presence of the cytokines FL, TPO, SCF and IL6. However, it is not clear from these studies whether SRC were expanded after 2 weeks of culture. The prolonged duration of the cultures would limit the usefulness of this expansion technique in a clinical setting.
There is ample evidence for the supportive role of stroma in the maintenance of stem cells and progenitors. [20] [21] [22] Verfaillie et al 23 demonstrated that the absolute number of stem cells (LTC-IC) and the colony-forming cell production in long-term cultures was increased after propagation of hematopoietic stem cells derived from normal BM in stroma-noncontact cultures.
14,23 O-sulphated GAGs seemed to be responsible for this long-term stroma-supported maintenance of LTC-IC in culture. 24 Brandt et al 12 showed that 3 weeks stroma-free culture of CD34 + Thy-1 + human BM cells with lineage-negative markers resulted in impairment of engraftment ability in NOD/SCID mice, which could be overcome by coculture with a layer of porcine microvascular endothelial cells. Additionally, we have previously reported that stroma-conditioned medium enhanced the expansion of primitive hematopietic stem/progenitor cells from CD34 + -selected mobilized peripheral blood in short-term cultures, while stroma support was also required for optimal maintenance and graft quality. 25, 26 Chih et al 27 have suggested LIF as the cytokine that is responsible for maintaining and expanding transplantable CD34 + Thy1 + cells in stroma-supported cultures through an action on the stroma. Our present results indicate that the addition of FL + TPO to the stroma-supported cultures significantly improved the expansion results in terms of nc, CD34
− cells, CFU-GM, CAFC subsets and estimated SRA. Surprisingly, in contrast to the stroma-free cultures, the addition of SCF ± IL6 to FL + TPO did not appear to substantially modify the extent of early progenitors, i.e. CAFC and estimated SRA. Although these data seem to contrast with several previous studies indicating that proliferation of hematopoietic stem cells in the presence of stroma is associated with loss of most in vivo repopulating ability, 28,29 it should be realised that FL and TPO were not exogenously added to the cultures in the latter studies. Recently, a study by Xu et al 30 has shown that CD34 +
CD38
− UCB cells after a 4-week culture period could maintain their in vivo repopulating ability. These cultures were supported by a stromal cell line derived from the aorta-gonad-mesonephros region of a 10.5 days postcoitum mouse embryo, a location currently considered to generate the first definitive hematopoietic stem cells. In our study, the expansion of CAFC and estimated SRA in FL + TPO stroma-supported cultures was as high as in stroma-free cultures in the presence of FL + TPO + SCF + IL6. These observations suggest that SCF and IL6, which is elaborated by the FBMD-1 stroma, was sufficient to compensate for the exogenously added SCF and IL6. It may be likely, that the increased SRA of cultured CD34
+ UCB cells is due to (1) an increase of the total SRC number; however, it is also possible that (2) quiescent SRC, or pre-SRC, are activated or recruited, respectively. Alternatively, it could be that (3) cultured cells show an increased ability to home either to, or expand in the BM of NOD/SCID mice, or that (4) there is a numerical or functional gain of facilitating cells that is possibly required for engraftment of the NOD/SCID BM by SRC. A study by Peled et al 31 showed that the chemokine stromal cell derived factor (SDF)-1 and its receptor CXCR4, which is expressed on some CD34 +
− cells amongst others, may be important for engraftment of sublethally irradiated NOD/SCID mice. The cytokines SCF and IL6 induced CXCR4 up-regulation on CD34 + cells, which subsequently potentiated migration of these precursor cells and their engraftment in primary and secondary transplanted mice. In addition, antibodies to CXCR4 completely prevented the engraftment in vivo. According to Cells infused into NOD/SCID mice were either uncultured, or propagated for 2 weeks in stroma-free or stroma-supported cultures. The inocula were either 50 000 (n = 13) or 100 000 (n = 4) CD34 
Table 3
Estimated fold-increase of the engraftment ability in NOD/SCID mice transplanted with cultured CD34 + UCB cells
Culture conditions Fold increase
Stroma-free cultures FL + TPO; n = 4 1 0 ± 8.5 FL + TPO + SCF; n = 4 12.5 ± 6 FL + TPO + IL6; n = 4 13.8 ± 5.8 FL + TPO + SCF + IL6; n = 3 12.6 ± 5.5 SCF + IL6; n = 3 2.6 ± 2.1
Stroma-supported cultures FL + TPO; n = 4 12.7 ± 2.8
The fold-expansion of the engraftment ability, in the cell dose ranges as used, was calculated on the assumption that there is a linear relation between the number of SCID repopulating cells transplanted and the level of chimerism in the bone marrow of NOD/SCID mice. The expansion data show the mean ± s.d. calculated in one experiment, in which each mouse was transplanted with 100 000 CD34 + uncultured cells or with 50 000 input equivalent cells after 2 weeks of culture. n, No. of mice.
these data, the use of at least SCF ± IL6 in our culture system might have caused increased homing potential of the CD34 
Figure 4
Engraftment ability of stroma-free and stroma-supported uncultured and 2 week cultured CD34 + UCB cells in bone marrow of NOD/SCID mice 6 weeks after transplantation. Mice were infused with either 50 000 (n = 13) or 100 000 (n = 4) CD34 + uncultured cells, or 50 000 (n = 4-15) input equivalent cultured CD34 6 and 0.2 to 11-fold the input for weektype 2 and 6, respectively) parallelled the estimated expansion of SRA (Table 3) , in contrast to the much more extensive increases in the total number of CD34 + CD38 − cells (five-to 1149-fold the input). The CAFC, SRA and CD34 + CD38 − cells are known to identify closely related populations in uncultured UCB, BM and MPB samples. The much more rapid increase of CD34 +
CD38
− cells compared to CAFC and estimated SRA indicates that these cell types may not detect the same cell populations after the culture period used.
In conclusion, hematopoietic stem/progenitor cells can be expanded in short-term cultures and stroma does not seem to be required for this purpose. If assessment of SRA and CAFC subsets are measures of in vivo repopulating stem cells in humans these findings may contribute to a rapid preparation of UCB grafts to meet the requirements for improved repopulation in the clinical setting.
Figure 5
Enhanced engraftment ability of 2 week stroma-free and stroma-supported cultured CD34
+ UCB cells in the bone marrow of NOD/SCID mice 6 weeks after transplantation. Mice were infused with either 100 000 (n = 4) uncultured CD34
+ cells or with 5000 (n = 3-4) and 50 000 (n = 3-4) input equivalent cultured CD34 
